Caliper to buy Xenogen in $80M deal
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Caliper Life Sciences |
Xenogen |
$80M buyout |
Xenogen makes cells, microorganisms and mice for research work. |
|
GlaxoSmithKline |
Pliva |
$50 million R&D buyout |
GSK acquires the R&D unit of Croatia's Pliva, which has specialized in developing antibiotics. |
|
Pliva |
Uso Racional |
Acquisition |
Pliva's buyout of Novartis' Spanish subsidiary fits into plan to focus on generics. |
|
Genospectra |
Panomics |
Merger |
Deal adds new operations for research reagents for transcription regulation, cell signaling and signal transduction. |
|
Elan Corporation |
Eisai |
Acquisition of European rights to Prialt |
The deal, for up to $100 million, nets Eisai the European market for the chronic pain therapy. |
|
Akzo Nobel's Intervet |
Bayer |
Facility acquisition |
Intervet adds a new vaccine production facility to its portfolio. |
|
Cambrex Bio Science Walkersville |
Cutanogen |
Acquisition |
The deal for $1.5 million in cash plus potential milestones adds business focused on treating severe burns. |
|
Wulfing Holding |
Myogen GmbH |
Acquisition |
Wulfing gains the European arm of Myogen and sublicenses heart failure therapy, Perfan IV. |